

Tetrahydroisoquinoline Sulfamates as Potent Microtubule Disruptors: Synthesis, Antiproliferative and Antitubulin Activity of Dichlorobenzyl-Based Derivatives, and a Tubulin Cocystal Structure

Wolfgang Dohle,[†] Andrea E. Prota,[‡] Grégory Menchon,^{‡,§} Ernest Hamel,[§] Michel O. Steinmetz,^{‡,||} and Barry V. L. Potter^{*,†}


[†]Medicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, U.K.

[‡]Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institute, Villigen PSI CH-5232, Switzerland

[§]Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, Frederick 21702, Maryland, United States

^{||}University of Basel, Biozentrum, Basel CH-4056, Switzerland

ABSTRACT: Tetrahydroisoquinoline (THIQ) 6-*O*-sulfamate-based anticancer agents, inspired by the endogenous steroid 2-methoxyestradiol and its sulfamate derivatives, are further explored for antiproliferative and microtubule disruptor activity. Based on recently designed C3-methyl C7-methoxy-substituted THIQ derivatives, compounds with mono- and dichloro-substitutions on the pendant *N*-benzyl ring were synthesized and evaluated. Although improved antiproliferative activity was observed, for example, **4a** versus **4b** and **4b** versus **8c**, it was relatively modest. Compound **8c**, a 2',5'-dichlorobenzyl derivative was, however, identified as a promising antiproliferative agent with in vitro activities exceeding that of the parent steroid (e.g., GI₅₀ 90 nM in DU-145 cells) and was highly potent against a range of tumor cell lines (e.g., GI₅₀ 26 nM for OVCAR-3). **8c** inhibited the polymerization of tubulin in vitro with an IC₅₀ only twofold less potent than combretastatin A-4 and inhibited colchicine binding to tubulin. Tubulin polymerization assays showed the parent THIQ **4a** to be only a very weak inhibitor, but a striking potency difference was seen between compounds with C2' methoxy and chloro substituents, whereas this was much smaller when these substituents were positioned at C5'. To confirm the target in atomic detail and because **8c** is a racemic mixture, an achiral parent THIQ 6-*O*-sulfamate derivative **10** was successfully cocrystallized with the $\alpha\beta$ -tubulin heterodimer. The derivative **10** binds at the colchicine site on tubulin, the first example of this compound class investigated in such detail, with its sulfamate group interacting with residues beyond the reach of colchicine itself, similar to a recently reported quinazolinone sulfamate derivative, **6a**. The structure also suggests that for racemic C3-methyl-substituted THIQ derivatives, such as **8c**, the (*S*)-enantiomer is likely to be preferentially accommodated within the colchicine site for steric reasons. The results further confirm the potential of nonsteroidal THIQ sulfamate derivatives for oncology and suggest that the mechanism of microtubule destabilization for the THIQ compound class is to prevent the curved-to-straight conformational transition of tubulin required for polymerization.



INTRODUCTION

In previous studies, we described *N*-benzyl-substituted tetrahydroisoquinoline (THIQ) derivatives as novel microtubule disruptors with potential therapeutic application for the treatment of cancer.^{1–5} These compounds were designed to mimic the 2-substituted estratriene class of microtubule disruptors derived from the endogenous steroid 2-methoxyestradiol (2ME) and, in particular, its sulfamate derivatives (e.g., **2a** (STX140), Figure 1).^{6–10} Incorporation of a phenolic 3-*O*-sulfamate group is generally observed to be highly beneficial for both activity and oral bioavailability, and STX140 is an optimized anticancer agent with both 3-*O*- and 17-*O*-sulfamate groups.¹¹ Agents possessing such sulfamate esters have reached multiple clinical trials in oncology and

elsewhere, primarily for hormone-dependent diseases.^{11,12} The sulfamoyl group can serve in diverse roles.¹²

STX140 was developed primarily for hormone-independent cancer applications, and the nonsteroidal THIQ core was used as a mimic of the steroidal AB-ring system from which steroidomimetics were constructed. Such compounds have markedly better physicochemical properties than 2ME and even STX140 but can maintain in vivo potency. Substitution of the THIQ nucleus at C6 and C7, with those groups requisite for activity in the steroidal series, was thus desirable.

Received: October 19, 2018

Accepted: December 24, 2018

Published: January 9, 2019




Figure 1. Design of dichlorobenzyl-substituted THIQ-based microtubule disruptors 7 and 8.

Attachment at N2 of a group projecting into the area of space occupied by the steroidal D-ring and bearing an H-bond acceptor known to be required for optimal activity completed the prototypical steroidmimetic design.^{1,2,11} Further optimization led to THIQs methylated at C3 forcing a more favorable conformation of the steroidal D-ring mimic by steric repulsion (THIQs of type 3 and 4, Figure 1).³ Related THIQ core chimeric microtubule disruptors possessing the trimethoxy aryl motif common to many tubulin colchicine site binders were designed and then further optimized.^{4,5} As a result, the best compounds in both series displayed nanomolar in vitro activities, making them equipotent or better than the steroidal derivatives that underpinned their design.^{3–5} Most recently, we designed another steroidal AB-ring mimic by using a dihydroquinazolinone (DHQ) core structure.¹³ The most potent DHQs derived from this series were also sulfamates of type 6 (Figure 1) with the best compounds again displaying nanomolar in vitro activities.

Like the steroids, the most potent heterocyclic derivatives were found to disrupt the polymerization of tubulin and inhibit the binding of [³H]colchicine to tubulin. THIQ sulfamates also inhibit carbonic anhydrases (CA) II,⁴ an interaction believed to contribute to the high oral bioavailability observed for the steroid derivatives,^{14,15} and CAIX,¹⁶ which affords extra targeting of hypoxic tumors. In addition, the activity of nonsteroidal THIQ derivatives mirrors that of the steroidal series, with compounds capable of inhibiting the growth of taxane-resistant cancer cells^{17–19} and human umbilical vein endothelial cell proliferation (a commonly used marker for antiangiogenic activity),^{20,21} thus supporting the idea that these small-molecule agents work in a similar manner to 2ME and its bis-*O*-sulfamate derivative **2a** (STX140).

Very recently, the mechanism of these heterocyclic sulfamate esters in the destabilization process of microtubule polymerization was investigated for the first time in atomic detail. The crystal structure of the most potent DHQ sulfamate of type 6, the *N*-(2',5'-dimethoxybenzyl) derivative **6a**, in complex with tubulin revealed molecular details to support further strategies for structure-based optimization. Interestingly, the sulfamate group was shown to play a role in binding at the colchicine site of tubulin. The mechanism of microtubule destabilization, at


least for this particular DHQ **6a**, was established as preventing the curved-to-straight tubulin conformational transition required for microtubule formation.^{13,22}

DHQ derivatives, although highly effective, are not charged at the linking N-atom. THIQ derivatives likely have more developmental potential, their charged nature in particular affording better solubility via salt formation at the N2 position. Moreover, they have been shown to be orally active in vivo when dosed in an aqueous buffer, with some being as potent as STX140.⁴ It was thus of interest to explore the potential for further optimization of such derivatives via new substitutions in the pendant aryl ring and, moreover, if this THIQ class could also be cocrystallized with the $\alpha\beta$ -tubulin heterodimer, such that atomic level information could be obtained, for further structure–activity relationship (SAR) development. In the present work, we explore the replacement of methoxy groups present in the steroidal D-ring mimic of C3-methylated THIQs with chloro substituents to determine whether such less polar and more lipophilic H-bond acceptors improve microtubule disruptor potency (Figure 1). Therefore, we introduced 2',3'-, 2',4'-, and 2',5'-dichlorobenzyl groups at N2 to explore SAR in a focused series of phenols and their sulfamate esters and explored their antiproliferative and antitubulin activities.

RESULTS AND DISCUSSION

Chemistry. The candidate THIQs were synthesized in two steps starting from ($\pm$)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-THIQ **9**.³ *N*-Benzylation using dichlorobenzyl halides, diisopropylethylamine (DIPEA) in *N,N*-dimethylformamide (DMF) at 140 °C for 18 h gave phenols **7a–c** in moderate yields. The target sulfamates **8a–c** were synthesized using sulfamoyl chloride as a solution in *N,N*-dimethylacetamide (DMA)²³ (Scheme 1).

Scheme 1. Synthesis of Dichloro-tetrahydroisoquinoline-Based Microtubule Disruptors^a



^aReagents and conditions: (i) ArCH₂X (X = Cl or Br), NaBr (for X = Cl), DIPEA, DMF, 140 °C, 18 h; (ii) H₂NSO₂Cl, DMA, rt.

Biology. All six compounds were evaluated at the US National Cancer Institute (NCI) in the full 60-cell-line assay that allows activity across a wide range of cancer types to be assessed (Tables 1 and 2). The in vitro activities of these compounds against DU-145 prostate and MDA MB-231 breast cancer cell line proliferation are shown in Table 1. Data from both cell lines are in strong agreement. Overall, compounds in this small series of N2-dichlorobenzyl C3-methyl-substituted THIQs exhibit activities in the micromolar and nanomolar ranges. Phenols **7b–c** are only about 3–5-fold less active than their corresponding sulfamates **8b–c** against the proliferation of DU-145 prostate cancer cells and MDA MB-231 breast cancer cells. The exception is phenol **7a** that proved to be more than 10-fold less active than its corresponding sulfamate, **8a**. GI₅₀ values of the sulfamates **8a–c** range between 90 nM (**8c**; DU-145) and 551 nM (**8a**; MDA MB-231). The best

Table 1. Antiproliferative Activity of Racemic THIQ Derivatives Against DU-145 Human Prostate and MDA MB-231 Human Breast Cancer Cells in Vitro from the NCI-60 Cell Line Panel^a

compd	R ¹	R ²	R ³	R ⁴	R ⁵	GI ₅₀ (μM)	
						DU-145	MDA MB-231
4a	SO ₂ NH ₂	OMe	H	H	OMe	0.371 0.189 ^b	2.1 0.16 ^b
4b	SO ₂ NH ₂	Cl	H	H	OMe	0.085 0.4 ^b	0.299 0.4 ^b
7a	H	Cl	Cl	H	H	4.18	7.05
8a	SO ₂ NH ₂	Cl	Cl	H	H	0.301	0.551
7b	H	Cl	H	Cl	H	0.261	0.465
8b	SO ₂ NH ₂	Cl	H	Cl	H	0.195	0.365
7c	H	Cl	H	H	Cl	0.241	0.542
8c	SO ₂ NH ₂	Cl	H	H	Cl	0.090	0.324

^aGI₅₀ figures represent mean values from triplicate experiments. All compounds of type 4, 7, and 8 are racemic mixtures. ^bGI₅₀ values for 4a–b are additionally taken from the literature.³

THIQ 8c of this small SAR screening set proved slightly more potent or very similar to previously reported THIQs, 4a–b.³ However, data from the NCI-60-cell-line panel for 4a–b against DU-145 and MDA-MB 231 cells suggested that 8c is significantly more potent than 4a, but only about as potent as 4b. Overall, the antiproliferative activity was significantly improved when the 2'-methoxy group was replaced with a 2'-chloro substituent. However, no further enhancement was observed when the 5'-methoxy group too was replaced with a 5'-chloro substituent. As these (±)-C3 methyl-substituted THIQs adopt a steroid-like conformation with the substituent at C5' pointing into the same area of space as the steroidal C17 β-hydroxyl group,^{1–3} it seems likely that the substituent at C2' will sterically interact with the two hydrogens at C1. Therefore, only relatively small one-atom substituents such as chlorine seem well tolerated at the C2' position. Note that the hydrogen and fluoro substituents at C2' in combination with a C5' methoxy group were also very well tolerated.³ It seems that the only marginally larger C2' methoxy group could already force too much of an angle between the THIQ B-ring and the pendant N2-benzyl ring, resulting in a less favorable overall conformation, leading to a decrease in activity (4a; MDA MB-231: 2.1 μM). However, there seem to be less restrictions for the second H-bond acceptor at C5' and more

space might be available around that binding site. Note, of course, that in all cases here, the activities of racemic mixtures are being compared, with all usual caveats, but vide infra for further discussion on this point.

Additionally, data from six more tumor cell lines are presented along with the mean activity across the whole panel (MGM value; Table 2). The trend that emerged for these THIQ derivatives against the proliferation of DU-145 prostate cancer cells and MDA MB-231 breast cancer cells in vitro was essentially confirmed across the whole NCI 60-cell-line assay. It also confirms the potential of these *N*-dichlorobenzyl compounds against a broad range of cancer phenotypes with 8c, in particular, proving highly active (e.g., 26 nM in OVCAR-3; MGM = 129 nM). Over the whole 60-cell-line panel, compound 4b was slightly more potent (MGM = 102 nM; Table 2). Additionally, the trend mentioned above with regard to 4a–b and 8c seems to hold well. Overall 4b and 8c were about 4–5 times more potent than 4a.

To confirm the target for these, we established the activity of the sulfamoylated compounds, 8a–c as microtubule disruptors, alongside the established potent clinical microtubule disruptor, combretastatin A-4 (CA-4), initially in tubulin polymerization assays and alongside the previously reported THIQ sulfamate, 10⁵ (Table 3). Gratifyingly, the 2',5'-dichlorobenzyl derivative

Table 3. Activity of *N*-Dichlorobenzyl-Substituted THIQs as Tubulin Polymerization Inhibitors and [³H]Colchicine Binding (5 μM Inhibitor) to Tubulin^a

compd	tubulin assembly	colchicine binding
	IC ₅₀ (μM)	(% inhibition)
CA-4	0.54 ± 0.06	98 ± 0.1
4a	>20	8.2 ± 2
4b	1.7 ± 0.2	55 ± 5
8a	2.1 ± 0.2	35 ± 1
8b	1.4 ± 0.2	47 ± 2
8c	0.98 ± 0.06	67 ± 2
10	1.3 ± 0.01	49 ± 3

^aValues are the mean ± SD of at least two determinations. All compounds of type 4 and 8 are racemic mixtures. ^bData for 4a are taken from the literature.³

8c very effectively inhibited the assembly of tubulin, with an IC₅₀ of 0.98 μM, being only about 2-fold less potent than CA-4. The IC₅₀ in these tubulin-based assays, as is typical with antitubulin agents with potent cytotoxic activity, far exceeds

Table 2. Antiproliferative Activity of *N*-Dichlorobenzyl-Substituted THIQs against Various Other Cancer Cell Lines in Vitro from the NCI-60 Cell Line Panel^{a,b}

compd	GI ₅₀ (μM)						
	lung HOP-62	colon HCT-116	CNS SF-539	melanoma UACC-62	ovarian OVCAR-3	renal SN12-C	MGM
4a	0.504	0.446	0.331	0.584	0.298	1.64	0.562
4b	0.075	0.048	0.042	0.069	0.039	0.372	0.102
7a	3.69	4.61	4.39	4.37	2.64	5.83	5.01
8a	0.387	0.226	0.227	0.119	0.137	0.933	0.316
7b	0.427	0.34	0.235	0.596	0.201	0.668	0.457
8b	0.183	0.054	0.106	0.050	0.045	0.657	0.151
7c	0.33	0.26	0.132	0.448	0.17	0.706	0.324
8c	0.055	0.073	0.046	0.056	0.026	0.345	0.129

^aGI₅₀ figures are mean values from triplicate experiments. All compounds of type 4, 7, and 8 are racemic mixtures. MGM represents the mean concentration that caused 50% growth inhibition in all 60 cell lines. ^bGI₅₀ values for 4a–b are taken from the literature.³

the antiproliferative GI_{50} dose, at least in part because the GI_{50} values refer to the concentration in the media, not in the cells. Inhibition of colchicine binding to tubulin for these compounds was also determined relative to CA-4 for further proof of targeting, with **8c** being the overall best THIQ derivative to date showing 67% inhibition at 5 μ M (Table 3). It is reasonable to propose that these novel THIQs can, at least partially, be assumed to disrupt normal dynamic tubulin polymerization by interacting at the colchicine site. Also, this provides further evidence that methoxy groups as polar H-bond acceptors are not an essential requirement in the D-ring mimic. Overall, the tubulin assays showed a striking difference in potency between compounds with methoxy and chloro as the C2' substituents (**4a** vs **4b**), whereas the difference in potency is much smaller when these substituents are positioned at C5' (**4b** vs **8c**). But also, here, the C5' chloro compound **8c** displayed an improved IC_{50} and inhibition of colchicine binding than the corresponding C5' methoxy compound, **4b**.

As in previously published work on DHQs,¹³ we employed X-ray crystallography to determine the atomic level binding mode of a THIQ derivative within the $\alpha\beta$ -tubulin heterodimer (Figure 2A). To avoid complications that would arise from




Figure 2. Overall view of the T_2R -TTL-STX3451 complex structure. The α - and β -tubulin chains are in dark and light grey, respectively, TTL is in yellow/orange, and RB3 is in violet ribbon representation. The tubulin-bound STX3451 and the nonexchangeable guanosine 5'-triphosphate (GTP) molecules bound to α -tubulin are shown as sphere representations. The carbon atoms of STX3451 are colored in cyan.

using the racemic sulfamate, **8c**, we chose a highly potent nonracemic THIQ, [2-(3'-bromo-4',5'-dimethoxybenzyl)-7-methoxy-6-sulfamoyloxy-1,2,3,4-THIQ—STX3451, **10**], without the C3-methyl group chiral center that had been optimized earlier⁵ and which is not too dissimilar to **8c** in its antitubulin activities (Table 3). STX3451 exerts antiproliferative and antimetabolic effects, inducing apoptosis and involving autophagic processes in MDA-MB-231 metastatic breast and A549 epithelial lung carcinoma cells²⁴ and also induces cell death effectively in NF1 tumor cell lines.²⁵ It is therefore somewhat more attractive as a potential development candidate than **8c**.

Compound **10** was soaked into crystals formed by a protein complex composed of two $\alpha\beta$ -tubulin heterodimers, the stathmin-like protein RB3 and tubulin tyrosine ligase (termed T_2R -TTL),²⁶ and we solved the T_2R -TTL-**10** complex structure using X-ray crystallography to 2.4 Å resolution (Figures 2 and 3B, 4A; Table 4) (PDB ID 6HX8). STX3451




Figure 3. Crystal structure of the complex of tubulin with STX3451. (A) Structures of **10** (STX3451), colchicine, and **11**. (B) STX3451 binding mode within the $\alpha\beta$ -tubulin heterodimer. The α - and β -tubulin subunits are represented as dark and light gray ribbons, respectively. STX3451 carbon atoms and the nonexchangeable GTP molecule bound to α -tubulin are shown as cyan and orange spheres, respectively.

binds to the tubulin colchicine site²² at the intradimer interface created by residues from the strands β S8 and β S9 the helix β H8 of β -tubulin, and the loop α T5 of α -tubulin (Figure 4A). STX3451 is well accommodated within the binding site, displaying an extended “steroid-like” conformation. These data now provide the second cocrystal structure of an antitubulin agent that possesses a sulfamate group and the first one where the steroidal AB-ring system is mimicked by a THIQ core. Figure 4B shows a comparison of the new THIQ sulfamate binding mode within the colchicine site with that of the earlier DHQ sulfamate **6a**.¹³

The C-ring of STX3451 is buried into a hydrophobic pocket formed by the β -tubulin residues: β Val238, β Cys241, β Leu242, β Leu255, β Met259, β Ala316, β Ile318, β Ala354, β Thr376, and β Ile378 (Figure 4A). Moreover, the 4'-methoxy oxygen of the C-ring forms a water-mediated hydrogen bond to the main chain amide and carbonyls of β Cys241, β Gly237, and β Val238. The A-ring of STX3451 is stacked between the side chains of β Asn258 and β Lys352, and further stabilization is provided by hydrogen bonds between the sulfamate moiety and the side chains of β Lys352, β Asn349, and α Ser178, the main chain amide of α Val181, and the main chain carbonyl group of β Asn349. Compared to the DHQ derivative **6a**¹³ (PDB ID 5OSK), which possesses an amine group in the B-ring, no water-mediated interaction to the carbonyl groups of the side chain and main chain of α Asn101 and α Thr179 is observed for STX3451 (Figure 4B). Moreover, the 3'-bromo substituent of the C-ring in STX3451 forms a water-mediated hydrogen bond to the main chain carbonyl of β Val238, a space that is

Table 4. Refinement Statistics of T₂R-TTL-STX3451^a

Data Collection ^a	
space group	P2 ₁ 2 ₁ 2 ₁
Cell Dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	104.0, 155.6, 180.9
resolution (Å)	48.4–2.4 (2.46–2.40)
<i>R</i> _{merge} (%)	9.3 (266.0)
<i>R</i> _{meas} (%)	10.1 (288.9)
<i>R</i> _{pim} (%)	4.2 (115.8)
<i>I</i> / σ <i>I</i>	16.7 (0.8)
CC _{1/2} ^b	99.9 (29.4)
completeness (%)	100 (100)
redundancy	6.8 (6.6)
Refinement	
resolution (Å)	48.4–2.4
no. unique reflections	115 121
<i>R</i> _{work} / <i>R</i> _{free}	19.5/24.0
No. Atoms	
protein	17 324
ligand	104
water	303
Average B-Factors (Å ²)	
protein	91.3
ligand (chain B/D)	66.3/114.3
water	74.3
Wilson B-factor	63.9
R.m.s. Deviations	
bond lengths (Å)	0.002
bond angles (deg)	0.535
Ramachandran Statistics ^c	
favoured regions (%)	97.1
allowed regions (%)	2.9
outliers (%)	0

^aHighest shell statistics are in parentheses. ^bCC_{1/2} = percentage of correlation between intensities from random half-datasets.²⁹ ^cAs defined by MolProbity.³⁰

otherwise occupied by the 2'-methoxy group in **6a** (Figure 4B).

Recently, THIQ compound (±)-**11** (Figure 3A), which is the same as **10** but with an additional (±)-C3 methyl group as in the present **8c** compound series, was synthesized and evaluated.⁵ As it was found to be similar to **10** (STX3451) in antitubulin assays (IC₅₀ 2.4 μM, 50% inhibition of colchicine binding⁵ vs IC₅₀ 1.3 μM and 49%, respectively) (Table 3, but note the very slightly different assay conditions), we would suggest that the additional (±)-C3 methyl group of the present series should, in principle, be well accommodated, as presumably also the 2',5'-dichloroaryl motif. This former feature was not an issue in the DHQ **6a** instance (see Figure 4B) because a planar carbonyl group occupies the C3 position. A closer inspection of the C3 environment in the tubulin-STX3451 crystal structure reveals that there may be enough space to accommodate both enantiomers of compound **11** (Figure 3A). However, we modeled compound **11** in both the (R)- and (S)-configurations into the STX3451 structure without energy minimization and inspected the C3 environment of both the enantiomers (Figure 5). The model suggests that the (S)-enantiomer likely binds without any structural rearrangements, whereas the (R)-enantiomer would clash into helix βH8, thereby requiring structural adaptations to get accommodated into the pocket or even preventing binding.

For these reasons, we expect that administration of the racemate would preferentially select for the (S)-enantiomer binding to tubulin. It is tempting to view the respective antitubulin IC₅₀ values of (±)-**11** and **10** in the light of this (2.4 and 1.3 μM) and speculate that (R)-**11** might be a very weak inhibitor or even totally inactive. The antitubulin activity of racemic 3-methyl-substituted THIQs, such as **8c**, may therefore actually be an underestimate if the (R)-enantiomer is not accommodated or only binds weakly in the colchicine site because of the structural adaptations necessary. Exploration of this possibility must however await the resolution of the isomers but, given the greater development potential of the achiral THIQ sulfamate **10**, this has not been pursued. Further development of these THIQs through medicinal chemistry might include the introduction of a (±)-C4 hydroxyl group as it could attract a water-mediated interaction to the carbonyl groups of the side chain and main chain of αAsn101 and αThr179, as was observed for DHQ **6a**.¹³

We further compared the binding mode of STX3451 **10** with that of colchicine by superimposition of both β-tubulin chains of their tubulin-ligand complexes (Figure 6; PDB ID 4O2B; rmsd of 0.428 Å over 393 C α -atoms of chains B). Tubulin undergoes a “curved-to-straight” conformational change when polymerized into microtubules,^{22,27} involving an overall compaction of the colchicine binding site through mainly the βT7 loop and βS8 strand of the β-tubulin chain.²² As already observed for the DHQ derivative **6a**,¹³ both compound poses show similarity and reveal that the respective A rings and associated methoxy groups of STX3451 and colchicine are very well superimposed, whereas the more flexible C ring of STX3451 is more extended. Both compounds, STX3451 and **6a**, share a unique and common polar interaction with the sulfamoyl group of the main chain of αVal181. As a result of the different shapes of the molecules (STX3451 vs colchicine), major conformational changes of both the αT5 and βT7 loops are observed (Figure 6). In summary, the results have established STX3451 **10** as a tubulin-binding ligand at the colchicine site in atomic detail. They also imply that **10**, similar to other colchicine-site ligands,^{22,28} achieves microtubule destabilization mechanistically by preventing the curved-to-straight conformational transition.

CONCLUSIONS

THIQ sulfamate-based microtubule disruptors have been further explored. Racemic N2-dichlorobenzyl C3-methyl-substituted THIQs showed excellent in vitro activities in the NCI-60-cell-line assays and antitubulin properties. Chlorine substitution for methoxy was found to be effective, and **8c** in particular exhibits antiproliferative activity in the 90 nM range, inhibiting tubulin assembly and interfering effectively with the colchicine site. To explore tubulin binding at the atomic level without the complication of chirality, a parent THIQ STX3451 **10** was cocrystallized successfully with the αβ-tubulin heterodimer. STX3451 binds more deeply in the colchicine site than colchicine itself, and the sulfamate group is involved in binding through specific interactions with β-tubulin residues beyond those accessed by colchicine. This is the first example of a THIQ derivative bearing a sulfamate ester bound to tubulin to be explored in such detail. With subtle differences, **10** adopts a broadly similar binding pose to a related DHQ derivative. Structural implications derived from the ligand are that C3 methyl group substitutions, as in the dichlorobenzyl




Figure 4. Detailed interaction of the tubulin-STX3451 complex. (A) Detailed view of the interaction network seen between STX3451 (aquamarine) and tubulin (gray). Residues of tubulin that interact are labeled and shown in stick representation. Oxygen and nitrogen atoms are colored red and blue, respectively, and carbon atoms are represented as aquamarine (STX3451) or gray (tubulin). Hydrogen bonds are shown as black dashed lines, and secondary structural elements of tubulin are labeled in blue. For simplicity, only α -tubulin residues and secondary structural elements are marked with an α . (B) Same close-up view as in (A) with the superimposed DHQ, 6a (pale yellow; PDB ID 5OSK; root-mean-square deviation of 0.20 Å over 409 C_{α} -atoms) structure. (C) Same close-up view as in (A) with the final 2mFo-DFc (blue) and mFo-DFc (green and red) electron density maps contoured at 1.0 σ and $\pm 3.0\sigma$, respectively. The green electron density blob marked with an arrow suggests an alternate conformation of the 5'-methoxy group of the C-ring. (D) Sigma A-weighted mFo-DFc (light green mesh) simulated annealing electron-density omit map contoured at 3.0 σ . The map was calculated excluding the atoms corresponding to STX3451 only. Both the STX3451 molecule (aquamarine sticks) and the two water molecules (red spheres, HOH) of the final refined structure are superimposed to highlight the quality of the map.




Figure 5. Molecular models of compound 11 in (A) (R)- and (B) (S)-configuration. Both enantiomers are shown in stick and semi-transparent surface representation. Carbon atoms are colored in red (A) and green (B). The tubulin backbone is in white and grey ribbon representation. Selected residue sidechains are in stick representation and are labeled. Secondary structural elements are labeled in blue. Chemical structures of compound 11 in (C) (R)- and (D) (S)-configuration.

derivatives, can be accommodated in the colchicine site. Modeling of (R)-11 and (S)-11 into the STX3451-tubulin structure further revealed that the (S)-enantiomer might be mainly responsible for the tubulin activity of such racemic C3 methyl-THIQ sulfamates as the C3 methyl group of the (R)-

Figure 6. Superimposition of the tubulin-STX3451 (lime/grey) and the tubulin-colchicine (violet; PDB ID 4O2B) complex structure in the same orientation and representation as in Figure 4A. The structures were superimposed onto their $\beta 1$ -tubulin chains.

enantiomer would sterically clash with tubulin residues. Most likely, mechanistically microtubule destabilization by STX3451 is via prevention of the curved-to-straight conformational transition of tubulin, as shown for colchicine and the STX3451-related quinazolinone DHQ derivative. With the usual caveats with regard to chirality, such compounds of this THIQ class are worthy development candidates for oncology.

EXPERIMENTAL SECTION

Tubulin Assays. Bovine brain tubulin was prepared as previously described³¹ and used in the studies presented. Assembly IC₅₀'s were determined as fully described elsewhere.³² In brief, 1.0 mg/mL (10 μ M) tubulin was preincubated with varying compound concentrations without GTP for 15 min at 30 °C. Reaction mixtures were placed on ice, and GTP (final concentration, 0.4 mM) was added. Mixtures were transferred to cuvettes held at 0 °C in a recording spectrophotometer. Baselines were established at 0 °C and increase in turbidity was followed for 20 min following a rapid (<30 s) jump to 30 °C. Concentrations of compound required to reduce the turbidity increase by 50% were determined. Inhibition of the binding of [³H]colchicine to tubulin was described fully previously.³³ Reaction mixtures contained 0.1 mg/mL (1.0 μ M) tubulin, 5.0 μ M [³H]-colchicine, and a potential inhibitor at 5.0 μ M. Compounds were compared to CA-4, a particularly potent inhibitor of colchicine binding to tubulin.³⁴ Mixtures were incubated for 10 min at 37 °C, a time point at which colchicine binding in control reaction mixtures is generally 40–60% complete.

Crystallization, Data Collection, and Structure Solution. Crystals of T₂R-TTL were generated as previously described.^{25,35} Crystals were soaked for 3 h at 20 °C in a reservoir solution (10% PEG 4K, 16% glycerol, 30 mM MgCl₂, 30 mM CaCl₂, and 0.1 M 2-(*N*-morpholino)ethanesulfonic acid/imidazole pH 6.7) containing 5 mM of compound 10 (STX3451) and subsequently transferred into a reservoir supplemented with 20% glycerol before cryo-cooling in liquid nitrogen. All data were collected at the Swiss Light Source (beamline X06DA, Paul Scherrer Institut, Villigen PSI, Switzerland) with images indexed and processed using XDS.³⁶ Structure solution using the difference Fourier method and refinement were performed using PHENIX³⁷ and model building was carried out iteratively using Coot software.³⁸ The atomic coordinates and structure factors have been deposited in the Protein Data Bank (www.rcsb.org) under accession number 6HX8 (T₂R-TTL-STX3451).

Structural Analysis and Figure Preparation. Molecular graphics and analyses were carried out using PyMol (The PyMOL Molecular Graphics System, Version 1.8.6.2, Schrödinger, LLC).

Chemistry. All chemicals were either purchased from Aldrich Chemical Co. (Gillingham, UK) or Alfa Aesar (Heysham, UK). Organic solvents of A.R. grade (PE, EtOAc, CHCl₃, acetone, and CH₂Cl₂) were supplied by Fisher Scientific (Loughborough, UK) and were used as supplied. Petroleum ether (PE) used for crystallization was of fractions 40–60 °C. DMA and DMF were purchased from Aldrich and stored under a positive pressure of N₂ after use. Sulfamoyl chloride was prepared using an adaptation of Appel and Berger methodology³⁹ and was stored in the refrigerator as a solution in toluene under a positive pressure of N₂, as described by Woo et al.⁴⁰ An appropriate volume was freshly concentrated in vacuo immediately before use. Compound 9 was synthesized according to a literature procedure.³ Reactions were performed at room temperature unless stated otherwise. Flash column chromatography was carried out on silica gel (Matrex C60). ¹H NMR spectra were recorded with a Varian Mercury VX 400 NMR spectrometer and a Bruker AVIII HD 400 spectrometer at 400 MHz. ¹³C NMR spectra were recorded with a Bruker AVIII HD 400 spectrometer at 100

MHz. Chemical shifts are reported in parts per million (ppm) relative to the solvent residual peaks as internal standards. ¹H NMR: 7.26 ppm (CDCl₃); 2.05 ppm (acetone-*d*₆). ¹³C NMR: 29.84 ppm (acetone-*d*₆). High resolution mass spectrometry was performed using a Bruker microTOF electrospray ionization mass spectrometer. Compounds were $\geq$ 96% pure by reversed-phase HPLC run with CH₃CN/H₂O or MeOH/H₂O (Sunfire C18 column, 4.6 $\times$ 150 mm, 3.5 μ m pore size).

($\pm$)-2-(2,3-Dichlorobenzyl)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline 7a. Compound 9 (386 mg, 2.0 mmol) was treated with 2,3-dichlorobenzyl bromide (506 mg, 2.1 mmol) and DIPEA (1.041 g, 8.0 mmol) in DMF (4.0 mL) at 140 °C for 18 h. After cooling to room temperature (RT), the reaction mixture was evaporated, then treated with H₂O (100 mL) and NH₄Cl (saturated, 10 mL) before extracting into EtOAc (2 $\times$ 100 mL). The combined organic layers were dried (NaCl), filtered, and evaporated. Purification by flash column chromatography (CHCl₃/acetone 9:1 $\rightarrow$ 9:1 and 2% MeOH) afforded compound 7a as a yellow solid (202 mg, 28%). ¹H NMR (400 MHz, CDCl₃): δ 1.14 (3H, d, *J* = 6.6), 2.52 (1H, dd, *J* = 16.1, 5.7), 2.94 (1H, dd, *J* = 15.9, 4.8), 3.14 (1H, sext, *J* 6.0), 3.56–3.90 (4H, m), 3.81 (3H, s), 5.42 (1H, s, br), 6.45 (1H, s), 6.66 (1H, s), 7.17 (1H, t, *J* 7.8), 7.35 (1H, dd, *J* 8.0, 1.3), and 7.50 (1H, d, *J* 7.0). LC/MS (ES⁺) *m/z*: 352.0 (M⁺ + H). HRMS (ES⁺) *m/z*: found 352.0872; C₁₈H₂₀Cl₂NO₂⁺, (M⁺ + H) requires 352.0866.

($\pm$)-2-(2,4-Dichlorobenzyl)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline 7b. Compound 9 (387 mg, 2.0 mmol), 2,4-dichlorobenzyl chloride (415 mg, 2.1 mmol), sodium bromide (41 mg, 0.4 mmol), and DIPEA (1.038 g, 8.0 mmol) in DMF (4.0 mL) were reacted at 140 °C for 18 h, as described for the synthesis of 7a. Purification by flash column chromatography (CHCl₃/acetone 9:1 $\rightarrow$ 9:1 and 2% MeOH) afforded compound 7b as a yellow solid (341 mg, 48%). ¹H NMR (400 MHz, CDCl₃): δ 1.14 (3H, d, *J* = 6.5), 2.51 (1H, dd, *J* = 16.1, 5.8), 2.92 (1H, dd, *J* = 16.2, 4.8), 3.12 (1H, sext, *J* 6.1), 3.53–3.80 (4H, m), 3.81 (3H, s), 5.42 (1H, s, br), 6.44 (1H, s), 6.65 (1H, s), 7.21 (1H, dd, *J* = 8.3, 2.1), 7.36 (1H, d, *J* 2.1), and 7.51 (1H, d, *J* 8.3). LC/MS (ES⁺) *m/z*: 352.0 (M⁺ + H). HRMS (ES⁺) *m/z*: found 352.0869; C₁₈H₂₀Cl₂NO₂⁺, (M⁺ + H) requires 352.0866.

($\pm$)-2-(2,5-Dichlorobenzyl)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline 7c. Compound 9 (387 mg, 2.0 mmol), 2,5-dichlorobenzyl chloride (413 mg, 2.1 mmol), sodium bromide (41 mg, 0.4 mmol), and DIPEA (1.035 g, 8.0 mmol) in DMF (4.0 mL) were reacted at 140 °C for 18 h, as described for the synthesis of 7a. Purification by flash column chromatography (CHCl₃/acetone 9:1 $\rightarrow$ 9:1 and 2% MeOH) afforded compound 7c as a yellow solid (275 mg, 39%). ¹H NMR (400 MHz, CDCl₃): δ 1.14 (3H, d, *J* = 6.6), 2.52 (1H, dd, *J* = 16.1, 5.9), 2.94 (1H, dd, *J* = 16.0, 5.0), 3.13 (1H, sext, *J* 6.1), 3.57–3.83 (4H, m), 3.82 (3H, s), 5.43 (1H, s, br), 6.46 (1H, s), 6.66 (1H, s), 7.14 (1H, dd, *J* = 8.5, 2.6), 7.26 (1H, d, *J* = 8.4), and 7.59 (1H, d, *J* = 2.5). LC/MS (ES⁺) *m/z*: 352.0 (M⁺ + H). HRMS (ES⁺) *m/z*: found 352.0875; C₁₈H₂₀Cl₂NO₂⁺, (M⁺ + H) requires 352.0866.

($\pm$)-2-(2,3-Dichlorobenzyl)-7-methoxy-3-methyl-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline 8a. Sulfamoyl chloride (0.63 M in toluene, 2.4 mL, 1.5 mmol) was concentrated in vacuo and cooled to 0 °C until the reagent solidified. DMA (2.0 mL) was added, and the resulting solution was added directly to 7a (176 mg, 0.5 mmol) at 0 °C. The reaction mixture was stirred at RT for 2 h. Sodium

bicarbonate (saturated, 50 mL) was added, and the mixture was extracted with EtOAc (100 mL). The organic layer was washed repeatedly with water (8 × 100 mL), then brine (2 × 5 mL), and then dried (MgSO₄) and evaporated. The residue was stirred in PE/CH₂Cl₂ (~20 mL, ~4:1) to afford compound **8a** as a pale yellow amorphous powder (150 mg, 69%). ¹H NMR (400 MHz, acetone-*d*₆): δ 1.17 (3H, d, *J* = 6.5), 2.59 (1H, dd, *J* = 16.1, 5.5), 2.99 (1H, dd, *J* = 16.1, 5.1), 3.22 (1H, sext, *J* = 6.0), 3.67 (1H, d, *J* = 16.0), 3.75 (1H, d, *J* = 16.0), 3.78 (3H, s), 3.84 (1H, d, *J* = 14.6), 3.97 (1H, d, *J* = 14.6), 6.79 (1H, s), 6.90 (2H, s, br), 7.07 (1H, s), 7.35 (1H, t, *J* = 7.8), 7.50 (1H, dd, *J* = 8.0, 1.6), and 7.53 (1H, dd, *J* = 7.9, 1.6). ¹³C NMR (100 MHz, acetone-*d*₆): δ 15.1 (CH₃), 35.2 (CH₂), 51.8 (CH₂), 53.6 (CH), 55.6 (CH₂), 56.2 (CH₃), 111.7 (CH), 124.8 (CH), 126.6 (C), 128.5 (CH), 129.9 (CH), 130.1 (CH), 132.6 (C), 133.3 (C), 134.0 (C), 138.7 (C), 140.4 (C), and 151.1 (C). LC/MS (ES⁺) *m/z*: 431.1 (M⁺ + H). HRMS (ES⁺) *m/z*: found 431.0602; C₁₈H₂₁Cl₂N₂O₄S⁺, (M⁺ + H) requires 431.0594.

(±)-2-(2,4-Dichlorobenzyl)-7-methoxy-3-methyl-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline 8b. The same method as for **8a** was followed using compound **7b** (317 mg, 0.9 mmol) and sulfamoyl chloride (0.63 M in toluene, 4.3 mL, 2.7 mmol) in DMA (3.6 mL) at RT for 2 h. The residue was stirred in PE/CH₂Cl₂ (~20 mL, ~4:1) to afford compound **8b** as a pale yellow amorphous powder (240 mg, 61%). ¹H NMR (400 MHz, acetone-*d*₆): δ 1.15 (3H, d, *J* = 6.5), 2.57 (1H, dd, *J* = 16.1, 5.5), 2.97 (1H, dd, *J* = 16.1, 5.0), 3.17 (1H, sext, *J* = 6.0), 3.63 (1H, d, *J* = 16.0), 3.72 (1H, d, *J* = 16.0), 3.75 (1H, d, *J* = 14.5), 3.78 (3H, s), 3.90 (1H, d, *J* = 14.5), 6.79 (1H, s), 6.89 (2H, s, br), 7.06 (1H, s), 7.37 (1H, dd, *J* = 8.3, 2.2), 7.47 (1H, d, *J* = 2.2), and 7.63 (1H, d, *J* = 8.3). ¹³C NMR (100 MHz, acetone-*d*₆): δ 15.1 (CH₃), 35.3 (CH₂), 51.8 (CH₂), 53.4 (CH), 54.4 (CH₂), 56.2 (CH₃), 111.6 (CH), 124.8 (CH), 126.7 (C), 128.0 (CH), 129.7 (CH), 132.9 (CH), 133.5 (C), 134.2 (C), 135.4 (C), 137.0 (C), 138.6 (C), and 151.1 (C). LC/MS (ES⁺) *m/z*: 431.1 (M⁺ + H). HRMS (ES⁺) *m/z*: found 431.0599; C₁₈H₂₁Cl₂N₂O₄S⁺, (M⁺ + H) requires 431.0594.

(±)-2-(2,5-Dichlorobenzyl)-7-methoxy-3-methyl-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline 8c. The same method as for **8a** was followed using compound **7c** (247 mg, 0.7 mmol) and sulfamoyl chloride (0.63 M in toluene, 3.4 mL, 2.1 mmol) in DMA (2.8 mL) at RT for 2 h. The residue was stirred in PE/CH₂Cl₂ (~20 mL, ~4:1) to afford compound **8c** as a pale yellow amorphous powder (185 mg, 61%). ¹H NMR (400 MHz, acetone-*d*₆): δ 1.17 (3H, d, *J* = 6.5), 2.59 (1H, dd, *J* = 16.2, 5.6), 3.00 (1H, dd, *J* = 16.1, 4.9), 3.21 (1H, sext, *J* = 6.0), 3.68 (1H, *J* = 16.0), 3.76 (1H, *J* = 16.0), 3.78 (3H, s), 3.79 (1H, *J* = 15.0), 3.92 (1H, *J* = 15.0), 6.81 (1H, s), 6.90 (2H, s, br), 7.08 (1H, s), 7.32 (1H, dd, *J* = 8.5, 2.7), 7.43 (1H, d, *J* = 8.5), and 7.67 (1H, d, *J* = 2.7). ¹³C NMR (100 MHz, acetone-*d*₆): δ 15.2 (CH₃), 35.2 (CH₂), 51.9 (CH₂), 53.6 (CH), 54.6 (CH₂), 56.2 (CH₃), 111.7 (CH), 124.9 (CH), 126.6 (C), 129.1 (CH), 131.0 (CH), 131.7 (CH), 133.0 (C), 133.3 (C), 134.0 (C), 138.6 (C), 140.1 (C), and 151.1 (C). LC/MS (ES⁺) *m/z*: 431.1 (M⁺ + H). HRMS (ES⁺) *m/z*: found 431.0605; C₁₈H₂₁Cl₂N₂O₄S⁺, (M⁺ + H) requires 431.0594.

AUTHOR INFORMATION

Corresponding Author

*E-mail: barry.potter@pharm.ox.ac.uk. Phone: +44 1865 271945 (B.V.L.P.).

ORCID

Michel O. Steinmetz: 0000-0001-6157-3687

Barry V. L. Potter: 0000-0003-3255-9135

Present Address

#Biotrial, 35000 Rennes, France.

Author Contributions

W.D. and A.E.P. contributed equally. All authors have given their approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

The content of this paper is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.

The structure of **10** (STX3451) bound to the T₂R-TTL complex has PDB access code 6HX8. Authors will release the atomic coordinates upon article publication

ACKNOWLEDGMENTS

Synthetic work was supported by Sterix Ltd., a member of the Ipsen Group. We thank the NCI DTP for providing in vitro screening resources. X-Ray data were collected at the Swiss Light Source (beamline X06DA, Paul Scherrer Institut, Villigen PSI, Switzerland). This work was supported by a grant from the Swiss National Science Foundation (31003A_166608 to M.O.S.). We thank Dr M. P. Leese for early discussions.

ABBREVIATIONS

THIQ, tetrahydroisoquinoline; 2ME, 2-methoxyestradiol; HUVEC, human umbilical vein endothelial cell; DHQ, dihydroquinazolinone; SAR, structure–activity relationship; DIPEA, diisopropylethylamine; DMF, *N,N*-dimethylformamide; DMA, *N,N*-dimethylacetamide; MGM, mean graph midpoint; GTP, guanosine 5′-triphosphate

REFERENCES

- (1) Leese, M. P.; Jourdan, F.; Dohle, W.; Kimberley, M. R.; Thomas, M. P.; Bai, R.; Hamel, M. R.; Ferrandis, E.; Potter, B. V. L. Steroidomimetic tetrahydroisoquinolines for the design of new microtubule disruptors. *ACS Med. Chem. Lett.* **2011**, *3*, 5–9.
- (2) Leese, M. P.; Jourdan, F. L.; Major, M. R.; Dohle, W.; Hamel, E.; Ferrandis, E.; Fiore, A.; Kasprzyk, P. G.; Potter, B. V. L. Tetrahydroisoquinoline-based steroidomimetic and chimeric microtubule disruptors. *ChemMedChem* **2013**, *9*, 85–108.
- (3) Dohle, W.; Leese, M. P.; Jourdan, F. L.; Major, M. R.; Bai, R.; Hamel, E.; Ferrandis, E.; Kasprzyk, P. G.; Fiore, A.; Newman, S. P.; Purohit, A.; Potter, B. V. L. Synthesis, anti-tubulin and anti-proliferative SAR of C-3/C-1 substituted tetrahydroisoquinolines. *ChemMedChem* **2014**, *9*, 350–370.
- (4) Leese, M. P.; Jourdan, F.; Kimberley, M. R.; Cozier, G. E.; Thiagarajan, N.; Stengel, C.; Regis-Lydi, S.; Foster, P. A.; Newman, S. P.; Acharya, K. R.; Ferrandis, E.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Chimeric microtubule disruptors. *Chem. Commun.* **2010**, *46*, 2907–2909.
- (5) Dohle, W.; Leese, M. P.; Jourdan, F. L.; Chapman, C. J.; Hamel, E.; Ferrandis, E.; Potter, B. V. L. Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors. *ChemMedChem* **2014**, *9*, 1783–1793.
- (6) Leese, M. P.; Hejaz, H. A. M.; Mahon, M. F.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. A-ring-substituted estrogen-3-

O-sulfamates: Potent multitargeted anticancer agents. *J. Med. Chem.* **2005**, *48*, 5243–5256.

(7) Bubert, C.; Leese, M. P.; Mahon, M. F.; Ferrandis, E.; Regis-Lydi, S.; Kasprzyk, P. G.; Newman, S. P.; Ho, Y. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 3,17-Disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: Synthesis, in vitro and in vivo anticancer activity. *J. Med. Chem.* **2007**, *50*, 4431–4443.

(8) Jourdan, F.; Bubert, C.; Leese, M. P.; Smith, A.; Ferrandis, E.; Regis-Lydi, S.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates: Synthesis, in vitro evaluation and computational modelling. *Org. Biomol. Chem.* **2008**, *6*, 4108–4119.

(9) Leese, M. P.; Leblond, B.; Smith, A.; Newman, S. P.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: Synthesis, in vitro SAR, protein crystallography, and in vivo activity. *J. Med. Chem.* **2006**, *49*, 7683–7696.

(10) Leese, M.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Alkylsulfanyl estrogen derivatives: Synthesis of a novel class of multi-targeted anti-tumour agents. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3135–3138.

(11) Thomas, M. P.; Potter, B. V. L. Discovery and development of the aryl O-sulfamate pharmacophore for oncology and women's health. *J. Med. Chem.* **2015**, *58*, 7634–7658.

(12) Potter, B. V. L. Steroid sulphatase inhibition via aryl sulphamates: clinic progress, mechanism and future prospects. *J. Mol. Endocrinol.* **2018**, *61*, T233–T252.

(13) Dohle, W.; Jourdan, F. L.; Menchon, G.; Prota, A. E.; Foster, P. A.; Mannion, P.; Hamel, E.; Thomas, M. P.; Kasprzyk, P. G.; Ferrandis, E.; Steinmetz, M. O.; Leese, M. P.; Potter, B. V. L. Quinazolinone-based anticancer agents: Synthesis, antiproliferative SAR, antitubulin activity, and tubulin co-crystal structure. *J. Med. Chem.* **2018**, *61*, 1031–1044.

(14) Elger, W.; Schwarz, S.; Hedden, A.; Reddersen, G.; Schneider, B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. *J. Steroid Biochem. Mol. Biol.* **1995**, *55*, 395–403.

(15) Ireson, C. R.; Chander, S. K.; Purohit, A.; Parish, D. C.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats. *Br. J. Cancer* **2004**, *91*, 1399–1404.

(16) Andring, J. T.; Dohle, W.; Chingkuang, T.; Potter, B. V. L.; McKenna, R. STX140 and Non-Steroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure Activity Optimization of Isoform Selectivity. *J. Med. Chem.* **2019**, in revision.

(17) Suzuki, R. N.; Newman, S. P.; Purohit, A.; Leese, M. P.; Potter, B. V. L.; Reed, M. J. Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyestradiol-bis-sulphamate and 2-ethyl-oestradiol-bis-sulphamate. *J. Steroid Biochem. Mol. Biol.* **2003**, *84*, 269–278.

(18) Newman, S. P.; Foster, P. A.; Stengel, C.; Day, J. M.; Ho, Y. T.; Judde, J.-G.; Lassalle, M.; Prevost, G.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. *Clin. Cancer Res.* **2008**, *14*, 597–606.

(19) Day, J. M.; Foster, P. A.; Tutill, H. J.; Newman, S. P.; Ho, Y. T.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. *Br. J. Cancer* **2009**, *100*, 476–486.

(20) Newman, S. P.; Leese, M. P.; Purohit, A.; James, D. R. C.; Rennie, C. E.; Potter, B. V. L.; Reed, M. J. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. *Int. J. Cancer* **2004**, *109*, 533–540.

(21) Chander, S. K.; Foster, P. A.; Leese, M. P.; Newman, S. P.; Potter, B. V. L.; Purohit, A.; Reed, M. J. In vivo inhibition of

angiogenesis by sulphamoylated derivatives of 2-methoxyestradiol. *Br. J. Cancer* **2007**, *96*, 1368–1376.

(22) Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature* **2004**, *428*, 198–202.

(23) Okada, M.; Iwashita, S.; Koizumi, N. Efficient general method for sulfamoylation of a hydroxyl group. *Tetrahedron Lett.* **2000**, *41*, 7047–7051.

(24) Nel, M.; Joubert, A.; Dohle, W.; Potter, B. V. L.; Theron, A. Modes of cell death induced by tetrahydroisoquinoline-based analogs in MDA-MB-231 breast and A549 lung cancer cell lines. *Drug Des. Dev. Ther.* **2018**, *12*, 1881–1904.

(25) Shen, Y.-C.; Upadhyayula, R.; Cevallos, S.; Messick, R. J.; Hsia, T.; Leese, M. P.; Jewett, D. M.; Ferrer-Torres, D.; Roth, T. M.; Dohle, W.; Potter, B. V. L.; Barald, K. F. Targeted NF1 cancer therapeutics with multiple modes of action: Small molecule hormone-like agents resembling the natural anti-cancer metabolite, 2-methoxyestradiol. *Br. J. Cancer* **2015**, *113*, 1158–1167.

(26) (a) Prota, A. E.; Bargsten, K.; Zurwerra, D.; Field, J. J.; Diaz, J. F.; Altmann, K.-H.; Steinmetz, M. O. Molecular mechanism of action of microtubule-stabilizing anticancer agents. *Science* **2013**, *339*, 587–590. (b) Gaspari, R.; Prota, A. E.; Bargsten, K.; Cavalli, A.; Steinmetz, M. O. Structural basis of *cis*- and *trans*-combretastatin binding to tubulin. *Chem* **2017**, *2*, 102–113. (c) Zhou, P.; Liu, Y.; Zhou, L.; Zhu, K.; Feng, K.; Zhang, H.; Liang, Y.; Jiang, H.; Luo, C.; Liu, M.; Wang, Y. Potent antitumor activities and structure basis of the chiral β -lactam bridged analogue of combretastatin A-4 binding to tubulin. *J. Med. Chem.* **2016**, *59*, 10329–10334.

(27) Brouhard, G. J.; Rice, L. M. The contribution of $\alpha\beta$ -tubulin curvature to microtubule dynamics. *J. Cell Biol.* **2014**, *207*, 323–334.

(28) Prota, A. E.; Danel, F.; Bachmann, F.; Bargsten, K.; Buey, R. M.; Pohlmann, J.; Reinelt, S.; Lane, H.; Steinmetz, M. O. The novel microtubule-destablizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. *J. Mol. Biol.* **2014**, *426*, 1848–1860.

(29) Karplus, P. A.; Diederichs, K. Linking crystallographic model and data quality. *Science* **2012**, *336*, 1030–1033.

(30) Davis, I. W.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MOLPROBITY: Structure validation and all-atom contact analysis for nucleic acids and their complexes. *Nucleic Acids Res.* **2004**, *32*, W615–W619.

(31) Hamel, E.; Lin, C. M. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. *Biochemistry* **1984**, *23*, 4173–4184.

(32) Hamel, E. Evaluation of antimetabolic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. *Cell Biochem. Biophys.* **2003**, *38*, 1–22.

(33) Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimetabolic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. *Mol. Pharmacol.* **1998**, *53*, 62–76.

(34) Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimetabolic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. *Biochemistry* **1989**, *28*, 6984–6991.

(35) Prota, A. E.; Magiera, M. M.; Kuijpers, M.; Bargsten, K.; Frey, D.; Wieser, M.; Jaussi, R.; Hoogenraad, C. C.; Kammerer, R. A.; Janke, C.; Steinmetz, M. O. Structural basis of tubulin tyrosination by tubulin tyrosine ligase. *J. Cell Biol.* **2013**, *200*, 259–270.

(36) Kabsch, W. Xds. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 125–132.

(37) Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P.

H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr.* **2010**, *66*, 213–221.

(38) Elmsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr.* **2004**, *60*, 2126–2132.

(39) Appel, R.; Berger, G. Über das hydrazidosulfamid (On hydrazidosulfamide). *Chem. Ber.* **1958**, *91*, 1339–1341.

(40) Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor *estra-1,3,5(10)-trien-17-one-3-sulphamate* inhibit estrone sulphatase by a different mechanism. *J. Steroid Biochem. Mol. Biol.* **1996**, *57*, 79–88.